No Data
No Data
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of CtDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
NeoGenomics (NASDAQ:NEO Shareholders Incur Further Losses as Stock Declines 3.2% This Week, Taking Three-year Losses to 69%
Express News | Neogenomics Inc : Piper Sandler Raises Target Price to $21 From $20
Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?
Morgan Stanley Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $18
Morgan Stanley analyst Tejas Savant maintains $NeoGenomics(NEO.US)$ with a hold rating, and adjusts the target price from $17 to $18.According to TipRanks data, the analyst has a success rate of 41.1%
Analysts Offer Insights on Healthcare Companies: American Well (AMWL), United Therapeutics (UTHR) and NeoGenomics (NEO)